Compare Essex Property Trust, Inc. (ESS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.6× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.66%). Which is the better fit depends on your goals.
| ESS | REGN | |
|---|---|---|
Market Cap | $18.20B | $83.19B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $812.27 |
52-Week Low | $239.61 | $545.94 |
Enterprise Value | $24.80B | $77.90B |
Dividend Yield | 3.66% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.
Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
